![](https://scx1.b-cdn.net/csz/news/tmb/2021/patient-2.jpg)
Axi-cel CAR T cell therapy shows enhanced responses and continued benefit for high-risk lymphoma patients
Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen ...
Dec 12, 2021
0
3